MA47678A - Plateforme personnalisée d'identification de peptide immunogène - Google Patents
Plateforme personnalisée d'identification de peptide immunogèneInfo
- Publication number
- MA47678A MA47678A MA047678A MA47678A MA47678A MA 47678 A MA47678 A MA 47678A MA 047678 A MA047678 A MA 047678A MA 47678 A MA47678 A MA 47678A MA 47678 A MA47678 A MA 47678A
- Authority
- MA
- Morocco
- Prior art keywords
- immunogenic peptide
- identification platform
- peptide identification
- personalized
- personalized immunogenic
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/605—MHC molecules or ligands thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17159242.1A EP3369431A1 (fr) | 2017-03-03 | 2017-03-03 | Vaccin |
EP17159243.9A EP3370065A1 (fr) | 2017-03-03 | 2017-03-03 | Peptides immunogènes |
GBGB1703809.2A GB201703809D0 (en) | 2017-03-09 | 2017-03-09 | Vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
MA47678A true MA47678A (fr) | 2021-05-26 |
Family
ID=61386864
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA047677A MA47677A (fr) | 2017-03-03 | 2018-03-02 | Vaccins peptidiques |
MA047683A MA47683A (fr) | 2017-03-03 | 2018-03-02 | Plate-forme d'identification de peptide immunogène reposant sur une population |
MA047678A MA47678A (fr) | 2017-03-03 | 2018-03-02 | Plateforme personnalisée d'identification de peptide immunogène |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA047677A MA47677A (fr) | 2017-03-03 | 2018-03-02 | Vaccins peptidiques |
MA047683A MA47683A (fr) | 2017-03-03 | 2018-03-02 | Plate-forme d'identification de peptide immunogène reposant sur une population |
Country Status (16)
Country | Link |
---|---|
US (9) | US20180264095A1 (fr) |
EP (3) | EP3589310A1 (fr) |
JP (4) | JP2020510698A (fr) |
KR (3) | KR102591136B1 (fr) |
CN (3) | CN110651189A (fr) |
AU (3) | AU2018226566A1 (fr) |
BR (3) | BR112019018307A2 (fr) |
CA (3) | CA3054861A1 (fr) |
CL (4) | CL2019002532A1 (fr) |
CO (3) | CO2019010503A2 (fr) |
IL (3) | IL268919B2 (fr) |
MA (3) | MA47677A (fr) |
MX (3) | MX2019010461A (fr) |
SG (3) | SG11201907524UA (fr) |
WO (3) | WO2018158457A1 (fr) |
ZA (2) | ZA201904723B (fr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016235388B2 (en) * | 2015-03-20 | 2022-02-03 | Children's National Medical Center | Generating virus or other antigen-specific T cells from a naive T cell population |
CN110651189A (zh) | 2017-03-03 | 2020-01-03 | 特雷斯生物公司 | 肽疫苗 |
MA53543A (fr) | 2018-09-04 | 2021-07-14 | Treos Bio Ltd | Vaccins peptidiques |
GB201814361D0 (en) | 2018-09-04 | 2018-10-17 | Treos Bio Zrt | Immunogenetic cancer screening test |
GB201814362D0 (en) | 2018-09-04 | 2018-10-17 | Treos Bio Zrt | Composition and process for preparing vaccine |
US11945850B2 (en) * | 2018-09-17 | 2024-04-02 | Immatics Biotechnologies Gmbh | B*44 restricted peptides for use in immunotherapy against cancers and related methods |
TW202039535A (zh) * | 2018-12-18 | 2020-11-01 | 德商英麥提克生物技術股份有限公司 | B*08限制肽和肽組合物抗癌免疫治療和相關方法 |
KR102159921B1 (ko) * | 2020-03-24 | 2020-09-25 | 주식회사 테라젠바이오 | 펩타이드 서열 및 hla 대립유전자 서열을 이용하여 신생항원을 예측하는 방법 및 컴퓨터 프로그램 |
JP2023520562A (ja) | 2020-04-03 | 2023-05-17 | ペップティーシー ヴァクシーンズ リミテッド | コロナウイルスワクチン |
GB202004974D0 (en) | 2020-04-03 | 2020-05-20 | Treos Bio Ltd | Coronavirus vaccine |
AU2020443560B2 (en) * | 2020-04-20 | 2024-03-21 | Nec Corporation | A method and a system for optimal vaccine design |
CN112048001B (zh) * | 2020-09-08 | 2022-04-05 | 南方科技大学 | 一种肿瘤新生抗原多肽及其应用 |
KR102278727B1 (ko) * | 2020-09-16 | 2021-07-19 | 주식회사 테라젠바이오 | 대상 암 조직 및 세포 유리형 dna 유래 펩타이드 서열 및 hla 클래스 ii 대립유전자 서열을 이용하여 신생항원을 예측하는 방법 및 컴퓨터 프로그램 |
EP4386762A1 (fr) | 2021-08-10 | 2024-06-19 | NEC Corporation | Système de traitement d'informations et procédé de traitement d'informations |
TW202322137A (zh) | 2021-10-04 | 2023-06-01 | 日商日本電氣股份有限公司 | 管理方法、管理系統及電子健康紀錄系統 |
WO2023059606A1 (fr) * | 2021-10-06 | 2023-04-13 | Cancervax, Inc. | Méthodes et compositions pour le traitement du cancer |
WO2023211024A1 (fr) * | 2022-04-27 | 2023-11-02 | 포항공과대학교 산학협력단 | Procédé de construction de molécules hybrides peptide-acide nucléique issues de points chauds reposant sur une sélection in vitro |
CN115785203B (zh) * | 2022-06-10 | 2024-03-12 | 河北博海生物工程开发有限公司 | 肺癌特异性分子靶标10及其用途 |
GB202216453D0 (en) | 2022-11-04 | 2022-12-21 | Lisziewicz Julianna | Identification of antigens which induce t-cell responses |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
BR9708161A (pt) | 1996-03-11 | 1999-07-27 | Epimmune Inc | Peptídeos com aumentada afinidade de ligação para moléculas hla |
US6617434B1 (en) | 1996-05-31 | 2003-09-09 | North Shore Long Island Jewish Research Institute | Identificiaton of differentially methylated and mutated nucleic acids |
US20030148463A1 (en) | 1997-04-14 | 2003-08-07 | Micromet Ag | Novel method for the production of anti-human antigen receptors and uses thereof |
EP0970126B1 (fr) * | 1997-04-14 | 2001-04-18 | Micromet AG | Nouveau procede de production de recepteurs d'anti-antigenes humains et leur utilisation |
FR2791895B1 (fr) | 1999-03-23 | 2001-06-15 | Pasteur Merieux Serums Vacc | Utilisation de trehalose pour stabiliser un vaccin liquide |
AUPQ776100A0 (en) | 2000-05-26 | 2000-06-15 | Australian National University, The | Synthetic molecules and uses therefor |
US6673580B2 (en) | 2000-10-27 | 2004-01-06 | Genentech, Inc. | Identification and modification of immunodominant epitopes in polypeptides |
US7892559B2 (en) | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
CN1691964A (zh) | 2002-09-06 | 2005-11-02 | 曼康公司 | 表位序列 |
GB0228900D0 (en) | 2002-12-11 | 2003-01-15 | Ml Lab Plc | Cancer Immunotherapy |
US20060257852A1 (en) | 2003-04-10 | 2006-11-16 | Chiron Corporation | Severe acute respiratory syndrome coronavirus |
US20050100883A1 (en) | 2003-11-12 | 2005-05-12 | Wang Chang Y. | Peptide-based diagnostic reagents for SARS |
CN101434647A (zh) | 2004-01-20 | 2009-05-20 | 爱知县 | 由HLA-A2402-限制的Ep-CAM-特异的CTL识别的表位/肽及其应用 |
WO2005118626A2 (fr) | 2004-06-01 | 2005-12-15 | Innogenetics N.V. | Peptides destines a induire une reponse ctl et/ou htl au virus de l'hepatite c |
US8487076B1 (en) | 2005-01-25 | 2013-07-16 | Nec Corporation | HLA-binding peptide, and DNA fragment and recombinant vector coding for said HLA-binding peptide |
CN103169958A (zh) | 2005-02-04 | 2013-06-26 | 萨瓦克公司 | 存活蛋白肽疫苗 |
CN100402554C (zh) * | 2005-02-25 | 2008-07-16 | 李玉新 | 睾丸特异性蛋白50人源抗体的制备及用途 |
FR2891462B1 (fr) | 2005-09-30 | 2009-10-16 | Commissariat Energie Atomique | Epitopes t cd4+ de la survivine et leurs applications |
GB0520067D0 (en) | 2005-10-01 | 2005-11-09 | Cancer Rec Tech Ltd | Treatment of cancer |
WO2008035350A1 (fr) | 2006-09-21 | 2008-03-27 | Vaxil Biotherapeutics Ltd. | Vaccins à multiples épitopes spécifiques à un antigène |
US8129184B2 (en) | 2006-09-26 | 2012-03-06 | Cedars-Sinai Medical Center | Cancer stem cell antigen vaccines and methods |
EP2361930A3 (fr) | 2007-03-26 | 2011-10-26 | Dako Denmark A/S | Multimeres du complexes peptide-cmh et leur utilisation dans des maladies infectieuses de borrelia |
EP2042600A1 (fr) | 2007-09-28 | 2009-04-01 | Commissariat A L'energie Atomique | Epitope de cellule CD4+ T publique et immunogène de la protéine tat vih et ses applications |
CN101981187A (zh) | 2008-03-31 | 2011-02-23 | 株式会社生物免疫平衡 | MHC Ⅱ类分子提呈的存活蛋白(Survivin)的部分肽及其利用方法 |
DK2119726T5 (en) | 2008-05-14 | 2018-03-26 | Immatics Biotechnologies Gmbh | Novel and powerful MHC class II peptides derived from survivin and neurocan |
TW201008574A (en) | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
EP2337795A2 (fr) | 2008-10-01 | 2011-06-29 | Dako Denmark A/S | Multimères de mhc dans des vaccins et la surveillance immunitaire contre le cancer |
GB0818065D0 (en) * | 2008-10-02 | 2008-11-05 | Cancer Rec Tech Ltd | Immunogenic peptides and uses thereof |
US20120244145A1 (en) * | 2009-11-16 | 2012-09-27 | Duke University | Enhanced immunological responses |
GB201004575D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
US20170039314A1 (en) * | 2010-03-23 | 2017-02-09 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
WO2012051282A2 (fr) * | 2010-10-14 | 2012-04-19 | The Ohio State University Research Foundation | Diagnostic et thérapie du cancer ciblés sur des protéines de type piwil2 (pl2l) |
EP2745845A1 (fr) * | 2012-12-19 | 2014-06-25 | Centre Hospitalier Universitaire de Bordeaux | Procédé de prévention ou de traitement d'une infection par VIH |
WO2014180490A1 (fr) | 2013-05-10 | 2014-11-13 | Biontech Ag | Prédiction de l'immunogénicité d'épitopes de lymphocytes t |
GB201315946D0 (en) | 2013-09-06 | 2013-10-23 | Immune Targeting Systems Its Ltd | Oncology vaccine |
IL292510A (en) * | 2013-11-05 | 2022-06-01 | Cognate Bioservices Inc | Combinations of checkpoint inhibitors and cancer drugs |
WO2015143335A1 (fr) | 2014-03-20 | 2015-09-24 | The University Of North Carolina At Chapel Hill | Méthodes et compositions pour protéines spike de coronavirus chimère |
EP3134104B1 (fr) | 2014-04-25 | 2018-12-26 | Tria Bioscience Corp. | Compositions de support d'haptène synthétique et procédés |
CA2961179A1 (fr) | 2014-09-14 | 2016-03-17 | Washington University | Vaccins anticancereux personnalises, et procedes correspondants |
WO2016090177A1 (fr) * | 2014-12-03 | 2016-06-09 | Verik Bio, Inc. | Identification, sélection et utilisation d'épitopes de cellule t à haut potentiel curatif |
JP7236216B2 (ja) | 2015-04-23 | 2023-03-09 | ナントミクス,エルエルシー | がんのネオエピトープ |
US11090332B2 (en) | 2015-05-21 | 2021-08-17 | Regen BioPharma, Inc. | Antigen specific mRNA cellular cancer vaccines |
JP2018532736A (ja) * | 2015-10-12 | 2018-11-08 | ナントミクス,エルエルシー | チェックポイント阻害物質への感受性を予測するmsiおよびネオエピトープの探索のための系、組成物、および方法 |
GB201604755D0 (en) | 2016-03-21 | 2016-05-04 | Vaxeal Res Sas | Immunogenic compositions |
JP2020503840A (ja) | 2016-10-07 | 2020-02-06 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | Hla拘束性vgll1ペプチドおよびその使用 |
MA47367B1 (fr) | 2017-01-27 | 2023-06-28 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers |
EP3369431A1 (fr) | 2017-03-03 | 2018-09-05 | Treos Bio Kft | Vaccin |
CN110651189A (zh) | 2017-03-03 | 2020-01-03 | 特雷斯生物公司 | 肽疫苗 |
EP3370065A1 (fr) | 2017-03-03 | 2018-09-05 | Treos Bio Kft | Peptides immunogènes |
WO2019133853A1 (fr) | 2017-12-28 | 2019-07-04 | Gritstone Oncology, Inc. | Protéines se liant à l'antigène ciblant des antigènes partagés |
US20210213066A1 (en) | 2018-05-18 | 2021-07-15 | Children's National Medical Center | Improved cell therapy compositions for hematopoietic stem cell transplant patients |
EP3796923A4 (fr) | 2018-05-18 | 2022-03-09 | Children's National Medical Center | Thérapie ciblée améliorée par lymphocytes t |
MA53543A (fr) | 2018-09-04 | 2021-07-14 | Treos Bio Ltd | Vaccins peptidiques |
GB201814362D0 (en) | 2018-09-04 | 2018-10-17 | Treos Bio Zrt | Composition and process for preparing vaccine |
GB201814361D0 (en) | 2018-09-04 | 2018-10-17 | Treos Bio Zrt | Immunogenetic cancer screening test |
EP3908292A4 (fr) | 2019-01-07 | 2023-01-04 | Children's National Medical Center | Thérapie améliorée à lymphocytes t ciblés pour le traitement du myélome multiple |
WO2020146434A2 (fr) | 2019-01-07 | 2020-07-16 | Children's National Medical Center | Compositions de lymphocytes t activées ex vivo et leurs procédés d'utilisation |
GB202004974D0 (en) | 2020-04-03 | 2020-05-20 | Treos Bio Ltd | Coronavirus vaccine |
-
2018
- 2018-03-02 CN CN201880014745.XA patent/CN110651189A/zh active Pending
- 2018-03-02 JP JP2019568815A patent/JP2020510698A/ja active Pending
- 2018-03-02 MX MX2019010461A patent/MX2019010461A/es unknown
- 2018-03-02 CA CA3054861A patent/CA3054861A1/fr active Pending
- 2018-03-02 BR BR112019018307-8A patent/BR112019018307A2/pt unknown
- 2018-03-02 EP EP18707725.0A patent/EP3589310A1/fr active Pending
- 2018-03-02 SG SG11201907524UA patent/SG11201907524UA/en unknown
- 2018-03-02 BR BR112019018312-4A patent/BR112019018312A2/pt unknown
- 2018-03-02 SG SG11201907402SA patent/SG11201907402SA/en unknown
- 2018-03-02 BR BR112019018313A patent/BR112019018313A2/pt unknown
- 2018-03-02 EP EP18710392.4A patent/EP3589951A1/fr active Pending
- 2018-03-02 AU AU2018226566A patent/AU2018226566A1/en active Pending
- 2018-03-02 MA MA047677A patent/MA47677A/fr unknown
- 2018-03-02 WO PCT/EP2018/055232 patent/WO2018158457A1/fr unknown
- 2018-03-02 CA CA3054871A patent/CA3054871A1/fr active Pending
- 2018-03-02 US US15/910,965 patent/US20180264095A1/en not_active Abandoned
- 2018-03-02 EP EP18707724.3A patent/EP3589954A1/fr active Pending
- 2018-03-02 US US15/910,930 patent/US20180264094A1/en not_active Abandoned
- 2018-03-02 AU AU2018228785A patent/AU2018228785A1/en active Pending
- 2018-03-02 JP JP2019568816A patent/JP7437939B2/ja active Active
- 2018-03-02 MA MA047683A patent/MA47683A/fr unknown
- 2018-03-02 CA CA3054866A patent/CA3054866A1/fr active Pending
- 2018-03-02 CN CN201880014727.1A patent/CN110651188B/zh active Active
- 2018-03-02 WO PCT/EP2018/055230 patent/WO2018158455A1/fr unknown
- 2018-03-02 KR KR1020197029094A patent/KR102591136B1/ko active IP Right Grant
- 2018-03-02 US US15/910,988 patent/US10213497B2/en active Active
- 2018-03-02 IL IL268919A patent/IL268919B2/en unknown
- 2018-03-02 AU AU2018228786A patent/AU2018228786A1/en active Pending
- 2018-03-02 MX MX2019010460A patent/MX2019010460A/es unknown
- 2018-03-02 KR KR1020197029093A patent/KR20190133177A/ko not_active Application Discontinuation
- 2018-03-02 MX MX2019010459A patent/MX2019010459A/es unknown
- 2018-03-02 MA MA047678A patent/MA47678A/fr unknown
- 2018-03-02 SG SG11201906765UA patent/SG11201906765UA/en unknown
- 2018-03-02 JP JP2019568814A patent/JP2020514413A/ja active Pending
- 2018-03-02 KR KR1020197029092A patent/KR102549625B1/ko active IP Right Grant
- 2018-03-02 WO PCT/EP2018/055231 patent/WO2018158456A1/fr unknown
- 2018-03-02 CN CN201880014739.4A patent/CN110621334A/zh active Pending
-
2019
- 2019-01-10 US US16/244,497 patent/US11213578B2/en active Active
- 2019-07-18 ZA ZA2019/04723A patent/ZA201904723B/en unknown
- 2019-07-18 ZA ZA2019/04725A patent/ZA201904725B/en unknown
- 2019-08-26 IL IL268917A patent/IL268917B2/en unknown
- 2019-08-26 IL IL26892019A patent/IL268920A/en unknown
- 2019-09-03 CL CL2019002532A patent/CL2019002532A1/es unknown
- 2019-09-03 CL CL2019002534A patent/CL2019002534A1/es unknown
- 2019-09-03 CL CL2019002533A patent/CL2019002533A1/es unknown
- 2019-09-26 CO CONC2019/0010503A patent/CO2019010503A2/es unknown
- 2019-09-26 CO CONC2019/0010524A patent/CO2019010524A2/es unknown
- 2019-09-27 CO CONC2019/0010698A patent/CO2019010698A2/es unknown
-
2021
- 2021-09-17 US US17/448,020 patent/US20220031823A1/en active Pending
- 2021-11-09 US US17/454,225 patent/US20220072114A1/en active Pending
- 2021-12-22 US US17/645,737 patent/US11426452B2/en active Active
- 2021-12-22 US US17/645,741 patent/US11628211B2/en active Active
-
2022
- 2022-10-14 CL CL2022002836A patent/CL2022002836A1/es unknown
- 2022-12-09 JP JP2022197534A patent/JP2023051941A/ja active Pending
-
2023
- 2023-02-08 US US18/166,420 patent/US20230405100A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA47678A (fr) | Plateforme personnalisée d'identification de peptide immunogène | |
DK3570884T3 (da) | Subkutane HER2-antistofformuleringer | |
MA52196A (fr) | Moyen d'identification de véhicule | |
MA43873A (fr) | Dspositif d'injection | |
DK3574182T3 (da) | Ledgenkendelsessystem | |
IT201600095893A1 (it) | Metodo per implementare realta' aumentata | |
ITUA20161350A1 (it) | Dispositivo di visione per realta' aumentata | |
ITUA20163609A1 (it) | "micro-cogeneratore". | |
DK3354160T3 (da) | Højde-justerbar platform | |
IT201700056835A1 (it) | Metodo per l'estrazione di proteine ricombinanti | |
IT201700090331A1 (it) | "lopemide" | |
IT201700071679A1 (it) | Remembebe' | |
IT201700112534A1 (it) | Capo d'abbigliamento | |
UA38201S (uk) | Пристрій для ін'єкцій | |
TH178766B (th) | "กระเป๋า" | |
MA51199A (fr) | Agents d'imagerie | |
MA46281A (fr) | Anticorps anti-muc16 (mucine 16) | |
UA36688S (uk) | Пляшка «ltava» | |
ITUA20162584A1 (it) | Capo d'abbigliamento. | |
IT201600105962A1 (it) | Pedana per attivita' ginniche. | |
GB201715609D0 (en) | Postie's friend | |
UA35785S (uk) | Пляшка «lotos» | |
ITUA20161486A1 (it) | Capo d'abbigliamento | |
ITUA20163709A1 (it) | "presentosa3d" | |
UA36320S (uk) | Етикетка «medovo!» |